INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Insights - Rezolute, Inc. experienced a significant decline in share price following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, which is aimed at treating congenital hyperinsulinism [1] - The clinical trial did not meet its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [1] Market Reaction - During intraday trading, Rezolute's shares plummeted from approximately $10.94 to an intraday low of around $0.90, reflecting an approximate 85–90% drop as trading was halted under Nasdaq's volatility controls [2]